ArticleTranslational oncology2015
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.
Article in Translational oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis.BMC cancer · 2022Pooled it
- Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.PloS one · 2021Pooled it
- The Role of p-STAT3 as a Prognostic and Clinicopathological Marker in Colorectal Cancer: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Investigation of potential prognostic biomarkers for colorectal cancer.Archives of medical science : AMS · 2025Article
- Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer.Cancer biology & therapy · 2024Review
- Review
- The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.Biomolecules · 2023Review
- Colon Cancer Screening Methods: 2023 Update.Cureus · 2023Review
- High Expression of IRS-1, RUNX3 and SMAD4 Are Positive Prognostic Factors in Stage I-III Colon Cancer.Cancers · 2023Article
- Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.British journal of cancer · 2022Article
- A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.Cancer reports (Hoboken, N.J.) · 2022Article
- Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.Clinical epigenetics · 2021Review
- Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development and Progression.International journal of molecular sciences · 2020Review
- Novel biomarkers for the diagnosis and prognosis of colorectal cancer.Intestinal research · 2020Review
- Ginkgolic Acid, a SUMO-1 Inhibitor, Inhibits the Progression of Oral Squamous Cell Carcinoma by Alleviating SUMOylation of SMAD4.Molecular therapy oncolytics · 2020Article
- Identification of NEO1 as a prognostic biomarker and its effects on the progression of colorectal cancer.Cancer cell international · 2020Article
- Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment.International journal of molecular sciences · 2019Review
- Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma.Journal of pathology and translational medicine · 2019Article
- SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSMAD4 immunohistochemistry is considered a valuable prognostic marker in colorectal cancer, but individual studies have often been small and the results variable. A meta-analysis could potentially clarify these findings.
methodsIn September 2014, a Pubmed and Google Scholar search was conducted to find publications that reported the prognostic value of SMAD4 expression. A meta-analysis was performed to clarify the association between SMAD4 expression and survival outcomes.
results137 studies were found, of which 13 were considered eligible. The studies consisted of a total of 3800 patients. Three different endpoints were taken into account, namely, overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). In addition, the studies were divided into univariate and multivariate analyses. The pooled hazard ratios were given as follows: univariate CSS = 1.75 [95% confidence interval (CI): 0.93-3.32; z= 1.69; P= .09]; multivariate CSS = 2.17 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate DFS = 2.11 (95% CI: 1.36-3.28; z= 3.32; P= .001); multivariate DFS = 2.15 (95% CI: 1.56-3.01; z= 4.65; P= .000); univariate OS and DFS = 2.30 (95% CI: 1.41-3.73; z= 3.36; P= .001); univariate OS = 2.28 (95% CI: 1.30-4.00; z= 2.89; P= .004).
conclusionThe results of the presented meta-analyses indicate that SMAD4 expression status using immunohistochemistry is a prognostic marker for patient survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.